



US008518919B2

(12) United States Patent
Dang et al.**(10) Patent No.: US 8,518,919 B2**
(45) Date of Patent: Aug. 27, 2013**(54) COMPOSITIONS COMPRISING**
AZELASTINE AND METHODS OF USE
THEREOF**(75) Inventors:** **Phuong Grace Dang**, Corona, CA (US);
Brian D. Lawrence, Somerset, NJ (US);
Gul Balwani, West Windsor, NJ (US);
Alexander D. D'Addio, Piscataway, NJ (US)**(73) Assignee:** **MEDA Pharmaceuticals Inc.**,
Somerset, NJ (US)**(*) Notice:** Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.**(21) Appl. No.:** **13/294,069****(22) Filed:** **Nov. 10, 2011****(65) Prior Publication Data**

US 2012/0149690 A1 Jun. 14, 2012

Related U.S. Application Data**(62)** Division of application No. 11/284,109, filed on Nov. 22, 2005, now Pat. No. 8,071,073.**(60)** Provisional application No. 60/630,274, filed on Nov. 24, 2004.**(51) Int. Cl.****A61K 31/55** (2006.01)**A61P 11/00** (2006.01)**A61P 27/14** (2006.01)**A61P 37/08** (2006.01)**(52) U.S. Cl.**USPC **514/171**; 514/2.3; 424/45; 424/465;
424/489**(58) Field of Classification Search**

None

See application file for complete search history.

(56) References Cited**U.S. PATENT DOCUMENTS**

158,564 A	1/1875	Barnes
2,119,643 A	6/1938	Mendl
2,136,940 A	11/1938	Ehbrecht
2,457,024 A	12/1948	Arp
2,822,314 A	2/1958	Ferlauto et al.
2,925,417 A	2/1960	Elslager et al.
2,995,308 A	8/1961	Ashkenaz
3,017,411 A	1/1962	Engelbrecht et al.
3,144,485 A	8/1964	Benn et al.
3,173,876 A	3/1965	Zobrist
3,267,586 A	8/1966	Molstedt et al.
3,541,005 A	11/1970	Strathmann et al.
3,541,006 A	11/1970	Bixler et al.
3,546,142 A	12/1970	Michaels et al.
3,753,988 A	8/1973	Rodway et al.
3,813,384 A	5/1974	Vogelsang et al.
3,845,052 A	10/1974	Stachel et al.
3,854,770 A	12/1974	Grise et al.
3,878,217 A	4/1975	Carr et al.
4,061,768 A	12/1977	Gorvin

4,077,407 A	3/1978	Theeuwes et al.
4,091,108 A	5/1978	Batchelor et al.
4,094,968 A	6/1978	Hodson et al.
4,226,848 A	10/1980	Nagai et al.
4,235,236 A	11/1980	Theeuwes
4,254,129 A	3/1981	Carr et al.
4,269,835 A	5/1981	Whittle
4,313,931 A	2/1982	Walther et al.
4,430,343 A	2/1984	Iemura et al.
4,435,440 A	3/1984	Hough et al.
4,449,983 A	5/1984	Cortese et al.
4,455,143 A	6/1984	Theeuwes et al.
4,495,170 A	1/1985	Beyts et al.
4,501,893 A	2/1985	Findlay et al.
4,570,630 A	2/1986	Elliott et al.
4,602,099 A	7/1986	Parker
4,621,094 A	11/1986	Findlay et al.
4,628,055 A	12/1986	Sherlock
4,704,285 A	11/1987	Alderman
4,704,387 A	11/1987	Engel et al.
4,728,509 A	3/1988	Shimizu et al.
4,738,984 A	4/1988	Parker
4,749,700 A	6/1988	Wenig

(Continued)

FOREIGN PATENT DOCUMENTS

AU	37674/72	7/1973
CA	2 455 939 A1	2/2003

(Continued)

OTHER PUBLICATIONSLa Force et al. in *Annals of Allergy, Asthma and Immunology* 76(2):181-188 (1996).*Wilson and Gisvold's *Textbook of Organic Medicinal and Pharmaceutical Chemistry*; Edition 11, published by Lippincott Williams and Wilkins (2004).*Ansel, Howard C., "Chapter 11—Ophthalmic Preparations," and "Chapter 13—Ear, Nose, and Topical Oral Formulations," in *Introduction to Pharmaceutical Dosage Forms*, Lea & Febiger, Philadelphia, PA., pp. 333-349 (1976).Banov, Charles H. and Lieberman, Phil, "Efficacy of Azelastine Nasal Spray in the Treatment of Vasomotor (Perennial Nonallergic) Rhinitis," *Ann. Allergy Asthma Immunol.* 86:28-35, American College of Allergy, Asthma, and Immunology (2001).

(Continued)

Primary Examiner — Dennis Heyer*(74) Attorney, Agent, or Firm* — Sterne, Kessler, Goldstein & Fox P.L.L.C.**(57)****ABSTRACT**

The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g., for the symptomatic relief of allergic rhinitis, non-allergic vasomotor rhinitis, allergic conjunctivitis, as well as other disorders.

20 Claims, No Drawings